ABSTRACT
Disease models are often used to obtain new information on the etiology and biology of human diseases and/or neoplasms and to develop new treatments. Although technological advances in clinical diagnosis and genetic analysis have further increased our understanding of the biology of diseases in recent years, models created with the contribution of genetic and tissue engineering to provide new biological perspectives to cellular and molecular etiology can provide a new platform. With the development of disease models that accurately reflect the mechanisms and results of tissue biology, data on the clinical features and genetic background of diseases are increasing day by day. Models that simply re-summarize diseases are indispensable to translate animal model-based research into a clinic and to contribute to the treatment strategies of these diseases. In this review, we present the models of common endocrine diseases and we emphasize the extent to which these models outline human biology and the main ideas collected from recent studies. We also presented the imaging modalities used in the diagnosis of these diseases in the light of recent studies.
References
1Moshkelgosha S, So PW, Diaz-Cano S, Banga JP. Preclinical models of Graves’ disease and associated secondary complications. Curr Pharm Des 2015;21:2414-2421.
2Ng HP, Banga JP, Kung AW. Development of a murine model of autoimmune thyroiditis induced with homologous mouse thyroid peroxidase. Endocrinology 2004;145:809-816.
3Shimojo N, Kohno Y, Yamaguchi K, et al. Induction of Graves like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci USA 1996;93:11074-11079.
4Rao PV, Watson PF, Weetman AP, Carayanniotis G, Banga JP. Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves’ disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination. Endocrinology 2003;144:260-266.
5Nagayama Y, McLachlan SM, Rapoport B, Niwa M. A major role for non-major histocompatibility complex genes but not for microorganisms in a novel murine model of Graves’ hyperthyroidism. Thyroid 2003;13:233-8.
6Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983;2:1115-1119.
7Sasazuki T, Inoko H, Morishima S, Morishima Y. Gene map of the HLA region, Graves’ Disease and hashimoto thyroiditis, and hematopoietic stem cell transplantation. Adv Immunol 2016;129:175-249.
8Kaithamana S, Fan J, Osuga Y, Liang SG, Prabhakar BS. Induction of experimental autoimmune Graves’ disease in BALB/c mice. J Immunol 1999;163:5157-5164.
9Banga JP, Nielsen CH, Gilbert JA, El Fassi D, Hegedus. Application of new therapies in Graves’ disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials. Thyroid 2008;18:973-981.
10Brandão J, Vergneau-Grosset C, Mayer J. Hyperthyroidism and hyperparathyroidism in guinea pigs (Cavia porcellus). Vet Clin North Am Exot Anim Pract 2013;16:407-420.
11Künzel F, Mayer J. Endocrine tumours in the guinea pig. Vet J 2015;206:268-274.
12Mayer J, Wagner R, Taeymans O. Advanced diagnostic approaches and current management of thyroid pathologies in Guinea pigs. Vet Clin North Am Exot Anim Pract 2010;13:509-23.
13Kim CS, Zhu X. Lessons from mouse models of thyroid cancer. Thyroid 2009;19:1317-1331.
14Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals crosscontamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-4341.
15Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170:793-804.
16Lakso M, Sauer B, Mosinger B Jr, et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA 1992;89:6232-6236.
17Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S. Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 2004;39:212-216.
18Antonello ZA, Nucera C. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene 2014;20;33:5397-5404.
19Greco A, Auletta L, Orlandella FM, et al. Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer. Int J Mol Sci 2017;18. pii: E2731.
20Tran Cao HS, Kaushal S, Snyder CS, Ongkeko WM, Hoffman RM, Bouvet M. Real-time imaging of tumor progression in a fluorescent orthotopic mouse model of thyroid cancer. Anticancer Res 2010;30:4415-4422.
21Imanishi Y, Hosokawa Y, Yoshimoto K, et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001;107:1093-1010.
22Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y, Saucier K. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 2002;17:N30-36.
23Kifor O, Diaz R, Butters R, Kifor I, Brown EM. The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells. J Biol Chem 273:21708-21713.
24Wortman JA, Alavi A, Attie M, Yudd AP, Johnston SA, Greenberg J. Quantitative autoradiography of parathyroid glands in rats with carbon-14-labeled amino acids. J Nucl Med 1987;28:1447-1452.
25Hyun H, Park MH, Owens EA, et al. Structure-inherent targeting of near-infrared fluorophores for parathyroid and thyroid gland imaging. Nat Med 2015;21:192-197.
26Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008;51:216-226.
27Shafrir E, Ziv E, Mosthaf L. Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models. Ann N Y Acad Sci 1999;892:223-246.
28Podell BK, Ackart DF, Richardson MA, DiLisio JE, Pulford B, Basaraba RJ. A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment. Dis Model Mech 2017;10:151-162.
29Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 2005;7:307-317.
30Ullrich M, Bergmann R, Peitzsch M, et al. Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics 2016;6:650-665.
31Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006;367:1605-1617.
32Lamberts SWJ. Glucocorticoid receptors and Cushing’s disease. Mol Cell Endocrinol 2002;197:69-72.
33Riebold M, Kozany C, Freiburger L, et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med 2015;21:276-280.
34Komori T. Animal models for osteoporosis. Eur J Pharmacol 2015;759:287-294.
35Takata S, Yasui N. Disuse osteoporosis. J Med Invest 2001;48:147-156.
36Moriishi T, Maruyama Z, Fukuyama R, et al. Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis. PLoS One 2011;6:e27487.
37Lucinda LMF, Aarestrup BJV, Reboredo MM, et al. Evaluation of the anti-osteoporotic effect of Ginkgo biloba L. in Wistar rats with glucocorticoid-induced-osteoporosis by bone densitometry using dual-energy x-ray absorptiometry (DEXA) and mechanical testing. An Acad Bras Cienc 2017;89:2833-2841.
